Please assess the completion status of the following clinical trial:

Trial Title: A Study of Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine FLU-Q-QIV in Adults Aged 18 Years and Older

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who the investigator believes that they can and will comply with the requirements of the protocol.~* Written informed consent obtained from the subject~* Male and female adults, 18 years of age and older in stable health as determined by investigator's clinical examination and assessment of subjects' medical history.~* Female subjects of non-childbearing potential may be enrolled in the study.~* Female subjects of childbearing potential may be enrolled in the study, if the subject:~  * has practiced adequate contraception for 30 days prior to vaccination, and~ * has a negative pregnancy test on the day of vaccination, and~ * has agreed to continue adequate contraception during the entire treatment period and for 2 months after completion of the vaccination~Exclusion Criteria:~* Administration of any influenza vaccine within 6 months preceding the study start or planned use of such vaccines during the study period.~* Administration of any other vaccine(s) within 30 days prior to study enrolment or during the study period.~* Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine within 30 days preceding the dose of study vaccine, or planned use during the study period.~* Acute disease and/or fever at the time of enrolment.~* Significant acute or chronic, uncontrolled medical or psychiatric illness.~* Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.~* Acute, clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, based on history and physical examination.~* Insulin-dependent diabetes mellitus.~* Presence of blood dyscrasias, including hemoglobinopathies and myelo- or lymphoproliferative disorder.~* Chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to study vaccine dose.~* A history of any demyelinating disease including Multiple Sclerosis and Guillain-Barré syndrome.~* Presence of an active neurological disorder.~* History of chronic alcohol abuse and/or drug abuse as deemed by the investigator to render the potential subject unable/unlikely to provide accurate safety reports.~* Any significant disorder of coagulation that increases the risk of intramuscular injections or treatment with coumadin derivatives or heparin. Persons receiving prophylactic anti-platelet medications, e.g. low-dose aspirin, and without a clinically apparent bleeding tendency are eligible~* Administration of immunoglobulins and/or any blood products within the three months preceding the administration of the study vaccine or planned during the study.~* Any known or suspected allergy to any constituent of FLU-Q-QIV and/or a history of anaphylactic type reaction to consumption of eggs, and/or reactions to products containing mercury.~* A history of severe adverse reaction to a previous influenza vaccination.~* Pregnant and/or lactating/nursing female.~* Any condition which, in the opinion of the investigator, prevents the subject from participation in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- FLULAVAL QUADRIVALENT Adult Group (Type: EXPERIMENTAL): Subjects 18-60 years of age received 1 dose of FLULAVAL® QUADRIVALENT vaccine at Day 0. The vaccine was administered intramuscularly in the deltoid of the non-dominant arm.
- FLULAVAL QUADRIVALENT Elderly Group (Type: EXPERIMENTAL): Subjects above 60 years of age received 1 dose of FLULAVAL® QUADRIVALENT vaccine at Day 0. The vaccine was administered intramuscularly in the deltoid of the non-dominant arm.

Based on this trial design, predict the completion outcome and termination type (if applicable).